Success of Direct-Acting, Antiviral-Based Therapy for Chronic Hepatitis C is Not Affected by Type 2 Diabetes

Published on May 31, 2019in Clinical Diabetes
路 DOI :10.2337/cd18-0112
Blake A. Niccum3
Estimated H-index: 3
(Harvard University),
Jonathan G. Stine2
Estimated H-index: 2
(Penn State Milton S. Hershey Medical Center)
+ 3 AuthorsNeeral L. Shah17
Estimated H-index: 17
(University of Virginia Health System)
IN BRIEF Chronic hepatitis C virus (HCV) is a risk factor for type 2 diabetes. In the era of interferon-based HCV therapy, type 2 diabetes was associated with decreased likelihood of sustained virologic response (SVR). Preliminary studies suggest that type 2 diabetes may not reduce the efficacy of regimens involving direct-acting antiviral (DAA) medications. We aimed to determine whether preexisting type 2 diabetes is associated with a reduced rate of SVR achieved 12 weeks after treatment of HCV with DAA-based regimens.
  • References (0)
  • Citations (0)
馃摉 Papers frequently viewed together
1 Citations
99 Citations
4 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
The incidence of both type 2 diabetes mellitus (T2DM) and multiple cancer types are rapidly increasing worldwide. Several studies documented that T2DM is closely associated with an increased incidence of cancer. However, while some methodological considerations preclude a definitive association between T2DM and the risk of certain cancers, the relationship between T2DM and increased risk of incident hepatocellular carcinoma (HCC) remains significant even after adjustment for detection bias and r...
17 CitationsSource
#2Catalina Suarez-Cuervo (Johns Hopkins University)H-Index: 15
Last. Mark S. SulkowskiH-Index: 77
view all 6 authors...
152 CitationsSource
Diabetes mellitus, insulin resistance and hepatitis C virus infection: A contemporary review
25 CitationsSource
#1Jonathan G. Stine (UVA: University of Virginia)H-Index: 13
#2Javelle A. Wynter (UVA: University of Virginia)H-Index: 1
Last. Neeral L. Shah (UVA: University of Virginia)H-Index: 17
view all 6 authors...
Abstract Introduction and aim. The effect of the new direct acting antiviral drugs (DAAs) for chronic hepatitis C (HCV) on glycemic control is unknown. Materials and methods. We conducted a retrospective cohort study of patients who were treated for chronic HCV with direct-acting antiviral medications at a single academic institution between May 2013 and April 2016. Univariate analysis was performed comparing subjects pre- and post-treatment. Results. One hundred seventy-five consecutive adult p...
3 CitationsSource
#1Kazuaki Chayama (Hiroshima University)H-Index: 89
#2Michio Imamura (Hiroshima University)H-Index: 31
Last. C. Nelson Hayes (Hiroshima University)H-Index: 26
view all 3 authors...
Summary There are estimated to be more than a hundred million hepatitis C virus (HCV) carriers worldwide. About 30% of carriers develop serious liver diseases, such as liver cirrhosis and hepatocellular carcinoma. HCV Genotype 1 is the most common genotype worldwide and the most difficult to treat with interferon-based therapy. Therapy for patients with chronic HCV infection is complicated by poor tolerability and inadequate rates of sustained virological response (SVR). Although the addition of...
7 CitationsSource
#1Hashem B. El-SeragH-Index: 101
#2Fasiha KanwalH-Index: 42
Last. Jennifer R. KramerH-Index: 38
view all 4 authors...
The long-term prognosis in terms of risk or predictors of developing hepatocellular carcinoma (HCC) among patients with sustained virological response (SVR) remains unclear. We conducted a retrospective cohort study using data from the Veterans Affairs VA hepatitis C virus (HCV) Clinical Case Registry in patients with positive HCV RNA between October 1999 and August 2009 and follow-up through December 2010. HCV treatment (interferon with or without ribavirin) and SVR (RNA test negative at least ...
171 CitationsSource
#1Paolo Pavone (Sapienza University of Rome)H-Index: 18
#2Tiziana TieghiH-Index: 6
Last. Vincenzo Vullo (Sapienza University of Rome)H-Index: 38
view all 10 authors...
Abstract Association between hepatitis C virus (HCV) infection and diabetes has been widely postulated. Little is known about the effect of direct-acting antiviral agents (DAAs) on glycaemic control. The aim of our study was to evaluate the glycaemic control modifications in a case series of HCV-positive diabetic patients receiving DAAs. We retrospectively evaluated 149 HCV-positive patients in two different institutions affiliated with Sapienza University: Policlinico Umberto I of Rome and Ospe...
34 CitationsSource
#1Adeel A. ButtH-Index: 41
#2Peng YanH-Index: 10
Last. Kenneth E. Sherman (University of Cincinnati Academic Health Center)H-Index: 56
view all 5 authors...
Background & Aims Sofosbuvir is widely prescribed for treatment of HCV infection. We compared the sustained virologic response rates (SVR12) and the haematologic toxicity of various sofosbuvir-based regimens in routine clinical practice. Methods We used ERCHIVES (Electronically Retrieved Cohort of HCV infected Veterans) to identify HCV-infected persons initiated on sofosbuvir-based regimens. Treatment duration and regimen were defined as per labelling guidelines. We excluded persons with HIV, po...
22 CitationsSource
#1Hashem B. El-Serag (BCM: Baylor College of Medicine)H-Index: 101
#2Fasiha Kanwal (BCM: Baylor College of Medicine)H-Index: 42
Last. Jennifer R. Kramer (BCM: Baylor College of Medicine)H-Index: 38
view all 4 authors...
144 CitationsSource
Hepatitis C virus (HCV) is a global challenge; 130-175 million are chronically infected. Over 350000 die each year from HCV. Chronic HCV is the primary cause of cirrhosis, hepatocellular carcinoma (HCC), and end-stage liver disease. Management of chronic HCV is aimed at preventing cirrhosis, reducing the risk of HCC, and treating extra hepatic complications. New treatments for chronic HCV has been devoted based on direct-acting antivirals, as pegylated interferon (peginterferon) is responsible f...
36 CitationsSource
Cited By0